GSK Strikes $20 Million Deal with 23andMe for Genetics Information Access

Why It Matters:

This deal is significant as it highlights the growing importance of genetics information in drug development and therapeutic research. It also showcases the power of the 23andMe research platform in providing valuable insights rooted in human genetics.

The Details:

• GSK and 23andMe have extended their collaboration through a $20 million one-year deal.

• The agreement allows GSK to access genetics information from 23andMe, aiding in the discovery of genetically validated targets for therapeutic development.

• Over the past five years, the collaboration between the two companies has resulted in approximately 50 successful programs.

• GSK's majority ownership of ViiV Healthcare, which has a significant operation in RTP, highlights the company's presence and impact in the Triangle region.

Conclusion:

The $20 million deal between GSK and 23andMe signifies the continued importance of genetics research in the pharmaceutical industry. This collaboration has the potential to yield valuable insights for therapeutic development, benefiting both companies and advancing the field of personalized medicine.